146 related articles for article (PubMed ID: 35313956)
1. Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
Vittecoq O; Guillou C; Hardouin J; Gerard B; Berenbaum F; Constantin A; Rincheval N; Combe B; Lequerre T; Cosette P
Arthritis Res Ther; 2022 Mar; 24(1):72. PubMed ID: 35313956
[TBL] [Abstract][Full Text] [Related]
2. Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response.
Obry A; Hardouin J; Lequerré T; Jarnier F; Boyer O; Fardellone P; Philippe P; Marcelli C; Loët XL; Vittecoq O; Cosette P
Theranostics; 2015; 5(11):1214-24. PubMed ID: 26379787
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
[TBL] [Abstract][Full Text] [Related]
5. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
[TBL] [Abstract][Full Text] [Related]
6. Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.
Gangadharan H; Singh A; Majumder S; Aggarwal A
J Clin Rheumatol; 2021 Dec; 27(8):e609-e611. PubMed ID: 33044386
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
Huffstutter JE; Kafka S; Brent LH; Matucci-Cerinic M; Tang KL; Chevrier M; Sprabery T; DeHoratius RJ
Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
[TBL] [Abstract][Full Text] [Related]
8. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.
Favalli EG; Becciolini A; Biggioggero M; Bertoldi I; Crotti C; Raimondo MG; Marchesoni A
Drug Des Devel Ther; 2018; 12():1421-1429. PubMed ID: 29872265
[TBL] [Abstract][Full Text] [Related]
9. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
[TBL] [Abstract][Full Text] [Related]
10. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
Kimura N; Suzuki K; Takeuchi T
Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
[TBL] [Abstract][Full Text] [Related]
11. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
13. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
14. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
Kaeley GS; Evangelisto AM; Nishio MJ; Goss SL; Liu S; Kalabic J; Kupper H
J Rheumatol; 2016 Aug; 43(8):1480-9. PubMed ID: 27307526
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
[TBL] [Abstract][Full Text] [Related]
20. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.
Obry A; Lequerré T; Hardouin J; Boyer O; Fardellone P; Philippe P; Le Loët X; Cosette P; Vittecoq O
PLoS One; 2014; 9(12):e115800. PubMed ID: 25546405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
